Investor and activist Dan Loeb turned all attention on Amgen when his firm, Third Point invested in the biotechnology company and suggested that the drug maker split. That was a week ago and Third Point said in its Oct. 21 investor letter- “It is well‐established that disparate business units generally benefit from operating separately due […]